This document provides an overview of a presentation on pharmaceutical packaging and development with a focus on pediatric formulations. It discusses choosing appropriate primary packaging, regulatory considerations, extractables and leachables testing, and packaging development processes. Specific topics covered include blister packs, bottles, closures, barrier properties of materials, desiccants, oxygen and water vapor transmission rates, and first intent guidelines.
This document discusses Quality By Design (QBD) approaches for packaging development. It begins by defining QBD and its key components, including Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), design space, and Quality Target Product Profile (QTPP). It emphasizes understanding how material attributes and process parameters impact CQAs. It also discusses identifying sources of variability and continuing monitoring throughout a product's lifecycle. The document then provides details on each step of QBD for packaging development, including concept development, product development, and industrialization. Concept development involves establishing QTPPs and CQAs based on customer needs and performing design experiments and analysis.
paharmaceutical packaging Medical device Packaging types of medical device p...RavichandraNadagouda
This document discusses pharmaceutical packaging and different types of packaging materials used. It begins by defining packaging and outlining its key functions of protection, preservation, presentation, and promotion. It then discusses ideal qualities for pharmaceutical packaging and types of packaging including primary, secondary, and tertiary packaging. The document focuses on primary packaging materials and medical device packaging, outlining different package types used and characteristics of materials like Tyvek, films, foils, and thermoformable plastics.
This document discusses pharmaceutical packaging, including types of packaging systems, materials used, and criteria for selection. It covers primary and secondary packaging, as well as common materials like glass, plastic, rubber, and paper. It also addresses specific dosage forms and how they relate to package forms, factors that influence packaging selection, and testing conducted on medical device packaging. The document provides a comprehensive overview of pharmaceutical packaging.
The document discusses the selection criteria for container closure systems for pharmaceutical products. There are four main criteria: 1) Protection - the container closure must protect the drug from factors like light, oxygen, and moisture that could degrade it. 2) Compatibility - the container and drug must not interact in ways that could affect drug stability or safety. 3) Safety - the materials used cannot leach harmful substances that the patient could be exposed to. 4) Performance - the container closure must function properly to deliver the drug as intended and support compliance. Compatibility testing, extraction studies, and functionality tests help evaluate different container closure systems.
Types of closures used for packaging of dosage forms include rubber closures, caps and overseals like screw caps and crown caps, and special types like tamper-evident, dispensing, and child-resistant closures. Rubber closures are commonly used and must pass fragmentation and self-sealability tests. Caps and overseals secure rubber closures and include screw caps, crown caps, snap on caps, and friction fit caps. Special closures provide features like tamper evidence, controlled dispensing, and child resistance. Proper closures are important to contain contents, provide barriers, allow resealing, and meet regulatory standards.
The document discusses packaging of pharmaceutical products. It describes the functions of packaging as presentation, identification, protection, convenience and containment. It outlines different types of packaging for solid, semi-solid and liquid products. It also discusses components of packaging including various materials used like glass, plastics, metals and rubbers. Different types of containers and closures are explained along with common packaging types like blister packs.
This presentation contains
Introduction, Advantages & Disadvantages, Process of manufacturing, Evaluation and defects in Blister, strip & ALU ALU Packaging. Useful for pharmacy students to understand the concept of blister & strip packaging
Pharmaceutical packaging serves several important purposes: protection, identification, information, containment, integrity, and stability. Packaging design must consider factors like material selection, sterility, and regulations. There are three levels of pharmaceutical packaging: primary, secondary, and tertiary. Primary packaging has direct contact with the product, while secondary and tertiary packaging provide additional protection, grouping, and handling during storage and shipping. Proper packaging is essential for medical products to maintain quality and safety throughout distribution and use.
This document discusses Quality By Design (QBD) approaches for packaging development. It begins by defining QBD and its key components, including Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), design space, and Quality Target Product Profile (QTPP). It emphasizes understanding how material attributes and process parameters impact CQAs. It also discusses identifying sources of variability and continuing monitoring throughout a product's lifecycle. The document then provides details on each step of QBD for packaging development, including concept development, product development, and industrialization. Concept development involves establishing QTPPs and CQAs based on customer needs and performing design experiments and analysis.
paharmaceutical packaging Medical device Packaging types of medical device p...RavichandraNadagouda
This document discusses pharmaceutical packaging and different types of packaging materials used. It begins by defining packaging and outlining its key functions of protection, preservation, presentation, and promotion. It then discusses ideal qualities for pharmaceutical packaging and types of packaging including primary, secondary, and tertiary packaging. The document focuses on primary packaging materials and medical device packaging, outlining different package types used and characteristics of materials like Tyvek, films, foils, and thermoformable plastics.
This document discusses pharmaceutical packaging, including types of packaging systems, materials used, and criteria for selection. It covers primary and secondary packaging, as well as common materials like glass, plastic, rubber, and paper. It also addresses specific dosage forms and how they relate to package forms, factors that influence packaging selection, and testing conducted on medical device packaging. The document provides a comprehensive overview of pharmaceutical packaging.
The document discusses the selection criteria for container closure systems for pharmaceutical products. There are four main criteria: 1) Protection - the container closure must protect the drug from factors like light, oxygen, and moisture that could degrade it. 2) Compatibility - the container and drug must not interact in ways that could affect drug stability or safety. 3) Safety - the materials used cannot leach harmful substances that the patient could be exposed to. 4) Performance - the container closure must function properly to deliver the drug as intended and support compliance. Compatibility testing, extraction studies, and functionality tests help evaluate different container closure systems.
Types of closures used for packaging of dosage forms include rubber closures, caps and overseals like screw caps and crown caps, and special types like tamper-evident, dispensing, and child-resistant closures. Rubber closures are commonly used and must pass fragmentation and self-sealability tests. Caps and overseals secure rubber closures and include screw caps, crown caps, snap on caps, and friction fit caps. Special closures provide features like tamper evidence, controlled dispensing, and child resistance. Proper closures are important to contain contents, provide barriers, allow resealing, and meet regulatory standards.
The document discusses packaging of pharmaceutical products. It describes the functions of packaging as presentation, identification, protection, convenience and containment. It outlines different types of packaging for solid, semi-solid and liquid products. It also discusses components of packaging including various materials used like glass, plastics, metals and rubbers. Different types of containers and closures are explained along with common packaging types like blister packs.
This presentation contains
Introduction, Advantages & Disadvantages, Process of manufacturing, Evaluation and defects in Blister, strip & ALU ALU Packaging. Useful for pharmacy students to understand the concept of blister & strip packaging
Pharmaceutical packaging serves several important purposes: protection, identification, information, containment, integrity, and stability. Packaging design must consider factors like material selection, sterility, and regulations. There are three levels of pharmaceutical packaging: primary, secondary, and tertiary. Primary packaging has direct contact with the product, while secondary and tertiary packaging provide additional protection, grouping, and handling during storage and shipping. Proper packaging is essential for medical products to maintain quality and safety throughout distribution and use.
Blister packaging involves enclosing pharmaceutical products like tablets and capsules in pre-formed plastic pockets. There are two main types of blister packs - thermoformed packs using heated plastic to form pockets and cold formed packs using aluminum foil. The key components are the forming film that creates the pockets, the lidding material that seals the top, a heat seal coating to bond them, and printing. Blister packs protect products and allow individual dosing. Machines for producing blister packs work by unwinding film, forming pockets, adding products, applying the lidding film, and sealing and cutting the finished packs.
This document discusses batch manufacturing records (BMRs), which are necessary quality and GMP documentation used to trace the complete manufacturing cycle of a batch or lot of a product. A BMR contains information about the batch including the batch number, size, composition, manufacturing record, weight of drug, shelf life, and storage conditions. It also includes general manufacturing instructions, a cleaning record of equipment used, a bill of materials listing raw materials, step-by-step manufacturing process details, yield calculations, a list of abbreviations, and a history of changes made to the document. A good BMR format contains all of this essential information.
Selection and evaluation of pharmaceutical packaging materialsTushar Naik
The document discusses the selection and evaluation of pharmaceutical packaging materials. It describes the key factors to consider when selecting packaging, including the drug properties, intended use conditions, and potential interactions. The main packaging materials discussed are glass, plastic, rubber, and metal. Glass types I-IV are outlined based on their chemical resistance. Compatibility tests for packaging include water attack testing of glass and evaluation of plastic containers for leakage, water permeability, and collapsability. Rubber closure testing involves sterility, residue levels, penetrability, and self-sealability. Proper packaging selection and evaluation helps ensure the drug product remains safe, stable and effective throughout its shelf life.
Analysis of raw material and finished productPRANJAY PATIL
This document summarizes key aspects of raw materials, quality control processes, and specifications for pharmaceutical products. It discusses criteria for selecting raw materials, roles of quality control in raw materials and finished products, and how specifications are developed and tested against. The summary focuses on establishing quality standards and controls from raw material selection through finished product release to ensure safety and efficacy.
This document discusses various aspects of packaging for sterile dosage forms. It begins by defining packaging and describing its purposes such as protecting products and preventing contamination. It then discusses different types of primary, secondary, and tertiary packaging as well as packaging materials like glass, plastic, rubber, and metals. Key characteristics and selection criteria for packaging materials are outlined. The document also covers packaging related topics such as quality assurance, sampling, testing, and validation.
This document discusses types of closures and closure liners used for containers. It describes five basic closure designs: screw on, crimp on, press on, roll on, and friction fit. It also discusses tamperproof, child resistant, and dispenser applicator variations. Common closure materials are plastic, metal, and laminates. Closure liners are used to create a seal and come in homogeneous one-piece or heterogeneous multi-layer designs. Selection factors for closures and liners include chemical inertness, permeability, stability, and economics. Regulations require packaging materials to preserve drug quality and safety.
This document discusses packaging and stability requirements for pharmaceuticals. It covers topics such as the purpose of pharmaceutical packaging in protecting drugs and ensuring stability. Various primary and secondary packaging materials are described, including glass, plastic and closures. The document also discusses packaging for different dosage forms like solids, liquids and medical devices. Key considerations for packaging include protection, compatibility, safety and performance. Packaging must meet regulations and standards to ensure drug quality and stability.
The document discusses plastic packaging materials used for pharmaceutical products. It begins by describing the two main categories of plastics - thermoplastics and thermosets. It then discusses potential interactions between drugs and plastic packaging, including permeation, leaching, sorption, and chemical reactions. Finally, it covers various closure and sealing methods that are approved by the FDA as tamper resistant packaging systems for pharmaceuticals, such as blister packs, bubble packs, foil/plastic pouches, and bottle seals.
Symbols Commonly Used in Medical Device Packaging and Labelingncor
This document lists various common symbols used in medical device packaging and labeling. It provides symbols for serial number, batch code, manufacturer, date of manufacture, caution, use by date, sterilization methods, non-sterile, single use, consult instructions, authorized representative, temperature limits, conformity assessment, non-ionizing radiation, shock protection type, general waste, sunlight, dry conditions, fragility, and recycling. The symbols are intended to clearly convey important information about medical devices on labels and packaging in accordance with international standards.
This document discusses various packaging materials and their evaluation. It covers primary, secondary and tertiary packaging. Glass, plastics, rubber and metals are described as packaging materials along with their advantages and limitations. Tests to evaluate glass, plastics and rubber are outlined including physicochemical and biological tests. Closures, labels and tamper-resistant packaging are also covered.
The document discusses form fill and seal (FFS) or blow fill seal (BFS) technology used in pharmaceutical packaging. BFS is a process where plastic containers are formed, filled with sterile product, and sealed in a single integrated machine within a sterile environment. It has become a prevalent aseptic processing technique over the last 20 years. The basic BFS process involves extruding a plastic tube, molding it into a container within the mold, filling the container, sealing it, and discharging the finished package. It reduces personnel and validation requirements compared to traditional packaging. While it has advantages like reduced costs, it also has challenges like particulate and temperature control that require mitigation strategies.
pharmaceutical shrink packaging (foil, plastic pouches, bottle seals, tape seals, breakable seals, sealed tubes)
pharmacy
technology
packaging
covers
plastics
Shrink packaging
Shrink packaging indicates the process in which sheets of transparent plastic film are wrapped around a product to form a solid, weather-resistant packaging layer.
Shrink packaging customarily refers to plastic films which have been pre-heated, stretched and cooled prior to use. This causes their initially randomly scattered molecules to align themselves in rigid structures, creating flat sheets of plastic film.
Shrink-wrap
When the shrink packaging films are applied to the product and re-heated, the molecules revert to their previous non-aligned state. This causes the plastic film to shrink and wrap itself tightly around the form and shape of the product (therefore the name ‘shrink-wrap’).
Stretch-wrap
When shrink packaging is simply stretched and wrapped around the product without being re-heated, it is known as ‘stretch-wrap’.
Benefits of shrink-packaging
Shrink packaging offers a versatile, cost-effective packaging solution for several reasons.
First, the materials used (plastic derivatives) are strong yet flexible, and provide effective protection, as well as making the product tamper-proof.
Second, shrink packaging is transparent, making it suitable for retail and wholesale display, and ideal for general marketing purposes due to its clear surface.
Third, shrink packaging is a relatively inexpensive option and ideal for low-cost packaging solutions.
Blow fill-seal technology for parentralDinesh Pawara
1. The document discusses parenteral plant layout and blow-fill-seal (BFS) and form-fill-seal (FFS) technology for sterile product formulation.
2. BFS and FFS are automated techniques that form, fill, and seal sterile containers in a closed system to reduce contamination risk compared to manual methods.
3. The basic BFS/FFS process involves extruding a tube of plastic, molding it into a container within a mold, filling the container, sealing it, and then ejecting the finished product. This is done within a sterile environment to produce products like vials and ophthalmic solutions aseptically.
The document discusses batch production record (BPR) review and release. It defines key terms like deviations, critical process parameters, critical quality attributes. It outlines regulatory requirements from ICH Q7, CFR 211, and consequences of non-compliance. The objectives of BPR review are to confirm the batch quality and was produced under control. Records of critical steps must be reviewed and approved by quality before release. Failure to comply with cGMPs can render a drug adulterated under the FDA act.
INTERVIEW QUESTIONS FOR TABLET PACKING – Latest Updates 2020JugrajSingh55
Pharmaceutical tablet packaging is an conceptual science some frequently asked Interview questions in tablet packaging are. What is Alu Alu packing? What is blister machine? What is strip packaging? What is the difference between strip and blister packaging? What are the advantages of blister packaging? How are blister packs
The pharmaceutical development report summarizes the development of a generic immediate-release acetriptan tablet using Quality by Design principles. Initial efforts focused on developing a discriminating dissolution method. Risk assessments guided formulation and process development studies. Formulation and process parameters were optimized through design of experiments. Scale-up plans were discussed and an exhibit batch demonstrated bioequivalence. A control strategy was proposed to ensure quality during routine manufacturing and product lifecycle.
Closures are devices used to seal containers like bottles and jars. They must provide an effective hermetic seal while preventing contents from escaping and external substances from entering. Common closure types include screw caps, crown caps, roll-on closures, and press-on caps. Closure quality is ensured through testing of materials, dimensions, extractables and leachables, bioburden, and sterilization validation. Proper closure selection and quality control ensures container integrity and product safety.
The document summarizes ICH guidelines for stability studies of new drug substances and products. It discusses the objectives and scope of stability testing, including providing evidence of a drug's quality over time under various environmental conditions to establish storage requirements and shelf life. The types of stability testing include chemical, physical, microbiological, therapeutic, and toxicological. Testing is conducted over various time periods and storage conditions as outlined in the ICH Q1A-Q1F guidelines. Evaluation of stability data includes assessing parameter results and using statistical analyses to determine a product's retest period or shelf life.
This document summarizes a training workshop on pharmaceutical development with a focus on pediatric formulations. It discusses considerations for pharmaceutical packaging for pediatric medicines, including choosing the most appropriate primary package, regulatory requirements, and packaging development. Specific topics covered include the roles of packaging, barrier properties of packaging, bottles and closures, blister packs, extractables and leachables testing, and packaging design through product launch.
Saurav anand iip process of pharma packaging developmenthncsaurav
This document discusses packaging development for pharmaceutical products. It outlines the process of selecting packaging, including identifying options, testing materials, development stability testing, defining manufacturing controls, selecting the intended market pack based on testing results, and conducting pivotal stability testing. The goals are to choose packs that ensure product stability and compatibility while meeting regulatory requirements and minimizing complexity. First intent packaging aims to standardize materials to reduce costs and variability across sites.
Blister packaging involves enclosing pharmaceutical products like tablets and capsules in pre-formed plastic pockets. There are two main types of blister packs - thermoformed packs using heated plastic to form pockets and cold formed packs using aluminum foil. The key components are the forming film that creates the pockets, the lidding material that seals the top, a heat seal coating to bond them, and printing. Blister packs protect products and allow individual dosing. Machines for producing blister packs work by unwinding film, forming pockets, adding products, applying the lidding film, and sealing and cutting the finished packs.
This document discusses batch manufacturing records (BMRs), which are necessary quality and GMP documentation used to trace the complete manufacturing cycle of a batch or lot of a product. A BMR contains information about the batch including the batch number, size, composition, manufacturing record, weight of drug, shelf life, and storage conditions. It also includes general manufacturing instructions, a cleaning record of equipment used, a bill of materials listing raw materials, step-by-step manufacturing process details, yield calculations, a list of abbreviations, and a history of changes made to the document. A good BMR format contains all of this essential information.
Selection and evaluation of pharmaceutical packaging materialsTushar Naik
The document discusses the selection and evaluation of pharmaceutical packaging materials. It describes the key factors to consider when selecting packaging, including the drug properties, intended use conditions, and potential interactions. The main packaging materials discussed are glass, plastic, rubber, and metal. Glass types I-IV are outlined based on their chemical resistance. Compatibility tests for packaging include water attack testing of glass and evaluation of plastic containers for leakage, water permeability, and collapsability. Rubber closure testing involves sterility, residue levels, penetrability, and self-sealability. Proper packaging selection and evaluation helps ensure the drug product remains safe, stable and effective throughout its shelf life.
Analysis of raw material and finished productPRANJAY PATIL
This document summarizes key aspects of raw materials, quality control processes, and specifications for pharmaceutical products. It discusses criteria for selecting raw materials, roles of quality control in raw materials and finished products, and how specifications are developed and tested against. The summary focuses on establishing quality standards and controls from raw material selection through finished product release to ensure safety and efficacy.
This document discusses various aspects of packaging for sterile dosage forms. It begins by defining packaging and describing its purposes such as protecting products and preventing contamination. It then discusses different types of primary, secondary, and tertiary packaging as well as packaging materials like glass, plastic, rubber, and metals. Key characteristics and selection criteria for packaging materials are outlined. The document also covers packaging related topics such as quality assurance, sampling, testing, and validation.
This document discusses types of closures and closure liners used for containers. It describes five basic closure designs: screw on, crimp on, press on, roll on, and friction fit. It also discusses tamperproof, child resistant, and dispenser applicator variations. Common closure materials are plastic, metal, and laminates. Closure liners are used to create a seal and come in homogeneous one-piece or heterogeneous multi-layer designs. Selection factors for closures and liners include chemical inertness, permeability, stability, and economics. Regulations require packaging materials to preserve drug quality and safety.
This document discusses packaging and stability requirements for pharmaceuticals. It covers topics such as the purpose of pharmaceutical packaging in protecting drugs and ensuring stability. Various primary and secondary packaging materials are described, including glass, plastic and closures. The document also discusses packaging for different dosage forms like solids, liquids and medical devices. Key considerations for packaging include protection, compatibility, safety and performance. Packaging must meet regulations and standards to ensure drug quality and stability.
The document discusses plastic packaging materials used for pharmaceutical products. It begins by describing the two main categories of plastics - thermoplastics and thermosets. It then discusses potential interactions between drugs and plastic packaging, including permeation, leaching, sorption, and chemical reactions. Finally, it covers various closure and sealing methods that are approved by the FDA as tamper resistant packaging systems for pharmaceuticals, such as blister packs, bubble packs, foil/plastic pouches, and bottle seals.
Symbols Commonly Used in Medical Device Packaging and Labelingncor
This document lists various common symbols used in medical device packaging and labeling. It provides symbols for serial number, batch code, manufacturer, date of manufacture, caution, use by date, sterilization methods, non-sterile, single use, consult instructions, authorized representative, temperature limits, conformity assessment, non-ionizing radiation, shock protection type, general waste, sunlight, dry conditions, fragility, and recycling. The symbols are intended to clearly convey important information about medical devices on labels and packaging in accordance with international standards.
This document discusses various packaging materials and their evaluation. It covers primary, secondary and tertiary packaging. Glass, plastics, rubber and metals are described as packaging materials along with their advantages and limitations. Tests to evaluate glass, plastics and rubber are outlined including physicochemical and biological tests. Closures, labels and tamper-resistant packaging are also covered.
The document discusses form fill and seal (FFS) or blow fill seal (BFS) technology used in pharmaceutical packaging. BFS is a process where plastic containers are formed, filled with sterile product, and sealed in a single integrated machine within a sterile environment. It has become a prevalent aseptic processing technique over the last 20 years. The basic BFS process involves extruding a plastic tube, molding it into a container within the mold, filling the container, sealing it, and discharging the finished package. It reduces personnel and validation requirements compared to traditional packaging. While it has advantages like reduced costs, it also has challenges like particulate and temperature control that require mitigation strategies.
pharmaceutical shrink packaging (foil, plastic pouches, bottle seals, tape seals, breakable seals, sealed tubes)
pharmacy
technology
packaging
covers
plastics
Shrink packaging
Shrink packaging indicates the process in which sheets of transparent plastic film are wrapped around a product to form a solid, weather-resistant packaging layer.
Shrink packaging customarily refers to plastic films which have been pre-heated, stretched and cooled prior to use. This causes their initially randomly scattered molecules to align themselves in rigid structures, creating flat sheets of plastic film.
Shrink-wrap
When the shrink packaging films are applied to the product and re-heated, the molecules revert to their previous non-aligned state. This causes the plastic film to shrink and wrap itself tightly around the form and shape of the product (therefore the name ‘shrink-wrap’).
Stretch-wrap
When shrink packaging is simply stretched and wrapped around the product without being re-heated, it is known as ‘stretch-wrap’.
Benefits of shrink-packaging
Shrink packaging offers a versatile, cost-effective packaging solution for several reasons.
First, the materials used (plastic derivatives) are strong yet flexible, and provide effective protection, as well as making the product tamper-proof.
Second, shrink packaging is transparent, making it suitable for retail and wholesale display, and ideal for general marketing purposes due to its clear surface.
Third, shrink packaging is a relatively inexpensive option and ideal for low-cost packaging solutions.
Blow fill-seal technology for parentralDinesh Pawara
1. The document discusses parenteral plant layout and blow-fill-seal (BFS) and form-fill-seal (FFS) technology for sterile product formulation.
2. BFS and FFS are automated techniques that form, fill, and seal sterile containers in a closed system to reduce contamination risk compared to manual methods.
3. The basic BFS/FFS process involves extruding a tube of plastic, molding it into a container within a mold, filling the container, sealing it, and then ejecting the finished product. This is done within a sterile environment to produce products like vials and ophthalmic solutions aseptically.
The document discusses batch production record (BPR) review and release. It defines key terms like deviations, critical process parameters, critical quality attributes. It outlines regulatory requirements from ICH Q7, CFR 211, and consequences of non-compliance. The objectives of BPR review are to confirm the batch quality and was produced under control. Records of critical steps must be reviewed and approved by quality before release. Failure to comply with cGMPs can render a drug adulterated under the FDA act.
INTERVIEW QUESTIONS FOR TABLET PACKING – Latest Updates 2020JugrajSingh55
Pharmaceutical tablet packaging is an conceptual science some frequently asked Interview questions in tablet packaging are. What is Alu Alu packing? What is blister machine? What is strip packaging? What is the difference between strip and blister packaging? What are the advantages of blister packaging? How are blister packs
The pharmaceutical development report summarizes the development of a generic immediate-release acetriptan tablet using Quality by Design principles. Initial efforts focused on developing a discriminating dissolution method. Risk assessments guided formulation and process development studies. Formulation and process parameters were optimized through design of experiments. Scale-up plans were discussed and an exhibit batch demonstrated bioequivalence. A control strategy was proposed to ensure quality during routine manufacturing and product lifecycle.
Closures are devices used to seal containers like bottles and jars. They must provide an effective hermetic seal while preventing contents from escaping and external substances from entering. Common closure types include screw caps, crown caps, roll-on closures, and press-on caps. Closure quality is ensured through testing of materials, dimensions, extractables and leachables, bioburden, and sterilization validation. Proper closure selection and quality control ensures container integrity and product safety.
The document summarizes ICH guidelines for stability studies of new drug substances and products. It discusses the objectives and scope of stability testing, including providing evidence of a drug's quality over time under various environmental conditions to establish storage requirements and shelf life. The types of stability testing include chemical, physical, microbiological, therapeutic, and toxicological. Testing is conducted over various time periods and storage conditions as outlined in the ICH Q1A-Q1F guidelines. Evaluation of stability data includes assessing parameter results and using statistical analyses to determine a product's retest period or shelf life.
This document summarizes a training workshop on pharmaceutical development with a focus on pediatric formulations. It discusses considerations for pharmaceutical packaging for pediatric medicines, including choosing the most appropriate primary package, regulatory requirements, and packaging development. Specific topics covered include the roles of packaging, barrier properties of packaging, bottles and closures, blister packs, extractables and leachables testing, and packaging design through product launch.
Saurav anand iip process of pharma packaging developmenthncsaurav
This document discusses packaging development for pharmaceutical products. It outlines the process of selecting packaging, including identifying options, testing materials, development stability testing, defining manufacturing controls, selecting the intended market pack based on testing results, and conducting pivotal stability testing. The goals are to choose packs that ensure product stability and compatibility while meeting regulatory requirements and minimizing complexity. First intent packaging aims to standardize materials to reduce costs and variability across sites.
PACKAGING OF TABLETS: TYPES, MATERIALS AND QC.Akshay Joshi
This document provides an overview of tablet packaging types, materials, and quality control. It discusses primary packaging formats like blister packs, bottles, and strip packs. Common materials include PVC, PVDC, aluminum, glass, and plastics. Quality is ensured through testing of water vapor transmission, oxygen transmission, and blister strength. A case study examines the stability of amoxicillin/clavulanic acid tablets under different packaging conditions.
The document discusses developing an analytical chemistry curriculum that prepares students for the future. It emphasizes building knowledge, skills, and attitudes. Key areas of focus include developing training programs, adopting quality standards, and promoting networking. Experiential learning is highlighted as an effective approach involving hands-on problem solving, simulations, and reflection. Systems thinking, continuous learning, and empowering people are also emphasized.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against developing mental illness and improve symptoms for those who already suffer from conditions like anxiety and depression.
The Olivet University conducts various extension classes, internship courses and various types of certificate courses in journalism with particular reference to biblical studies.
Specialty Papers 2014 taking place September 16-18, 2014 in Milwaukee, WI has expert presenters like Graham Moore taking the stage. Moore, a Smithers Pira consultant will be available to chat in Milwaukee!
validation of packaging issue by rahul sagar, bbau lucknowBrajesh Kumar
The document discusses packaging validation and quality assurance aspects for pharmaceutical products. It includes:
1. An overview of packaging materials, types of packaging, selection criteria and characteristics required for packaging materials.
2. Details of primary, secondary, and tertiary packaging as well as special packaging types like unit-dose and device packaging.
3. Blister and strip packaging are discussed in more detail including the components, manufacturing process, and common materials used.
Quality assurance ensures high quality packaging and compliance with regulations to avoid issues that could harm patients. Validation is important to confirm the packaging process meets requirements.
Packaging And Its Materia Properties Packaging Media Package Testing And Its ...Girish Kumar K
This document discusses various aspects of pharmaceutical packaging including package material properties, packaging media, and package testing. It describes the mechanical, physical, chemical, and biological properties that packaging materials must possess. It also outlines different types of packaging media like metals, plastics, paper, glass, and rubber. Finally, it covers testing procedures for packaging materials and complete packages to evaluate characteristics like strength, permeability, and compatibility.
The document discusses pharmaceutical packaging validation. It begins with introductions and definitions of packaging and packaging validation. It then discusses selection criteria for packaging materials, characteristics of materials, types of packaging and materials. The document outlines validation protocols and discusses visual inspection, identification testing, dimensional analysis, and microbiological testing during validation. It also describes blister packaging and strip packaging processes.
Validation of packaging operations PharmaDivesh Singla
The document discusses pharmaceutical packaging validation. It begins with introductions and definitions of packaging and packaging validation. It then discusses selection criteria for packaging materials, characteristics of materials, types of packaging and materials. The document outlines validation protocols and discusses visual inspection, identification testing, dimensional analysis, and microbiological testing during validation. It also describes blister packaging and strip packaging processes.
This document discusses packaging options for pharmaceutical products. It begins with an overview of factors to consider when choosing the most appropriate packaging, such as protection, commercial needs, and regulatory requirements. It then covers specific packaging types like bottles, blister packs, and closures. Details are provided on material properties, barrier performance, and development considerations for stability and compatibility. The goal of establishing packaging "first intent" standards is also mentioned to streamline processes and ensure a robust supply chain.
This document discusses packaging options for pharmaceutical products. It begins with an overview of factors to consider when choosing packaging, such as protection, commercial needs, and regulations. It then covers specific packaging types like bottles, blister packs, inhalers and more. For each type, it lists material and design options. It discusses regulatory guidance for packaging from the US and EU. Finally, it covers approvals needed for packaging materials that contact pharmaceutical products.
Packaging materials must protect sterile products, be non-reactive, and provide important product information to patients. There are primary, secondary, and associated packaging components. Primary components like vials and syringes contact the product directly, while secondary components provide additional protection. Glass, plastic, and rubber are common materials, each with advantages and limitations for packaging. Proper packaging selection is critical to avoid particulate, pyrogen, and stability issues.
This document discusses packaging for pharmaceutical products. It defines packaging and outlines the selection criteria and characteristics of packaging materials. The main types of packaging are primary, secondary, and tertiary. Common materials include glass, metals, plastics, rubbers, fibrous materials, and films/foils. Blister packs and strip packs are described as primary packaging forms. The document provides details on specific materials like aluminum and discusses packaging symbols.
The document discusses trends in flexible packaging and its applications. It notes that flexible packaging has evolved from an afterthought to a key marketing component. Global drivers include globalization, customer value, technology, and supply chain management. Flexible packaging helps reduce food waste by providing effective protection that preserves food quality and extends shelf life, as well as offering appropriate formats and serving sizes that minimize leftovers. Studies show individually packaged foods generate less waste than bulk formats. Flexible packaging is a partner in reducing food waste and supporting responsible consumption and production.
Global packaging use is expected to increase to $820 billion by 2016, with flexible and rigid plastics and board packaging formats seeing the most growth. Key packaging trends include smart packaging that provides consumer information via technologies like QR codes, convenient packaging that offers benefits like easy opening and microwavability, and retail ready packaging that is shelf ready. Sustainable packaging focuses on areas like bioplastics and the 3Rs of reduce, reuse, and recycle. Food packaging must ensure safety by preventing chemical interactions between packaging, food, and the environment according to regulations and standards.
This document discusses pharmaceutical packaging. It defines pharmaceutical packaging and describes the primary and secondary/tertiary packaging systems. The key requirements for pharmaceutical packaging are to protect the product, be non-reactive, prevent contamination, and be FDA approved. Important criteria for selecting packaging materials include stability, compatibility with contents, strength, moisture protection, and cost. Common packaging materials include glass, plastic, metal, paper, rubber, and closures. Guidelines for quality control of packaging materials require containers and closures to meet pharmacopeial standards and be properly washed and sterilized.
This document discusses various tests that are conducted on food packaging materials and packages. Some key tests mentioned include thickness testing, which measures the thickness of materials like paper and film using a dial or digital gauge under a constant pressure. Pinhole testing checks for pinholes in aluminum foil laminates, which can impact barrier properties. Peel or delamination testing measures the bond strength between layers in laminates. Seal strength testing determines the force required to separate seals in flexible pouches and laminates. Permeation tests quantify the barrier properties of plastic films to moisture vapor and gases like oxygen.
This document provides information on various tests for food packaging, including the purpose and importance of packaging testing. It discusses how testing new packaging designs can save time and money by identifying potential issues. It then classifies packaging tests into material tests and package tests, and further into chemical and mechanical tests. Several specific mechanical tests are described in detail, including GSM (grammage), thickness, pinhole testing of aluminum foil, peel bonding (delamination), seal strength, permeability, coefficient of friction, ink rub/scuff testing, and compression/burst testing of pouches. Standards for conducting each test are provided. The document serves as an educational reference on packaging testing methods.
The document discusses various topics related to packaging design, including:
- Packaging accounts for a large percentage of waste and its design impacts its sustainability.
- Key considerations for packaging design include technical and regulatory requirements, lifecycle costs and impacts, and social factors.
- Common packaging materials include various plastic films and foil laminates, with choices impacting barrier properties and recyclability.
This document summarizes a presentation about utilizing biopolymers for lightweighting parts in the transportation industry. The presentation discusses Innovative Plastics and Molding, a company that develops biopolymer technologies using wood and cellulose fillers. It identifies potential biopolymer applications in automobiles and discusses challenges with molding complex lightweight parts from reinforced thermoplastics. Requirements for successful biopolymer formulations, processing, and molded part performance are also outlined.
Food packaging properties and benefitsAnuKiruthika
Food packaging provides protection, prevents tampering, and meets physical and chemical needs for food. Packaging materials include glass, tinplate, aluminum, paper, paperboard, and plastics. Each material has unique properties that make it suitable for different packaging purposes and food types. For example, glass is inert and transparent but brittle, while plastics can be transparent, flexible at different temperatures, and vary widely in barrier properties. Proper selection of packaging materials and formats is important for automated food production operations to run efficiently.
Pharmaceutical Packaging tablet and capsulesGirish Sahu
This document discusses packaging of tablets, capsules, and powders. It defines packaging and describes the roles and types of packaging. The key types discussed are blister packages, strip packages, aluminum foil packaging, and bottle packaging. It also covers materials used for different types of packaging, emphasizing properties like barrier effectiveness. The document provides details on formation of blister and strip packages and evaluates packaging for leakage. It discusses use of desiccants and packaging of powders in pouches and bottles.
Packaging design & innovation in foods and beveragesinewtrition
Do you want to choose the right packaging for your new product?
Do you want to strengthen your existing product as part of your marketing strategy and consider the alternatives to your current packaging?
Creating or selecting a food package is partly art and partly science. Both are significant and go hand in hand. Besides, designers must evaluate the technology push, market pull and socioeconomics carefully for successful packaging design.
To average consumers, food packaging is simply the enclosure of a food product in a plastic pouch, a metal can, or a glass bottle. To scientists or engineers, food packaging is a rather technical subject – it is a coordinated system designed for the efficient delivery of high quality, safe food products throughout the supply chain and the shelf-life. However, for food entrepreneurs, food packaging is all the above and more. The packaging gives you innovative ways to reach your customers. It enables you to communicate with your consumers as a marketing tool. For more information, please contact Raphaelle at info@inewtrition.com
Level 3 NCEA - NZ: A Nation In the Making 1872 - 1900 SML.pptHenry Hollis
The History of NZ 1870-1900.
Making of a Nation.
From the NZ Wars to Liberals,
Richard Seddon, George Grey,
Social Laboratory, New Zealand,
Confiscations, Kotahitanga, Kingitanga, Parliament, Suffrage, Repudiation, Economic Change, Agriculture, Gold Mining, Timber, Flax, Sheep, Dairying,
Temple of Asclepius in Thrace. Excavation resultsKrassimira Luka
The temple and the sanctuary around were dedicated to Asklepios Zmidrenus. This name has been known since 1875 when an inscription dedicated to him was discovered in Rome. The inscription is dated in 227 AD and was left by soldiers originating from the city of Philippopolis (modern Plovdiv).
This document provides an overview of wound healing, its functions, stages, mechanisms, factors affecting it, and complications.
A wound is a break in the integrity of the skin or tissues, which may be associated with disruption of the structure and function.
Healing is the body’s response to injury in an attempt to restore normal structure and functions.
Healing can occur in two ways: Regeneration and Repair
There are 4 phases of wound healing: hemostasis, inflammation, proliferation, and remodeling. This document also describes the mechanism of wound healing. Factors that affect healing include infection, uncontrolled diabetes, poor nutrition, age, anemia, the presence of foreign bodies, etc.
Complications of wound healing like infection, hyperpigmentation of scar, contractures, and keloid formation.
How to Manage Reception Report in Odoo 17Celine George
A business may deal with both sales and purchases occasionally. They buy things from vendors and then sell them to their customers. Such dealings can be confusing at times. Because multiple clients may inquire about the same product at the same time, after purchasing those products, customers must be assigned to them. Odoo has a tool called Reception Report that can be used to complete this assignment. By enabling this, a reception report comes automatically after confirming a receipt, from which we can assign products to orders.
A Free 200-Page eBook ~ Brain and Mind Exercise.pptxOH TEIK BIN
(A Free eBook comprising 3 Sets of Presentation of a selection of Puzzles, Brain Teasers and Thinking Problems to exercise both the mind and the Right and Left Brain. To help keep the mind and brain fit and healthy. Good for both the young and old alike.
Answers are given for all the puzzles and problems.)
With Metta,
Bro. Oh Teik Bin 🙏🤓🤔🥰
1. Simon Mills | April 20081 |
Pharmaceutical Development with Focus
on Paediatric formulations
WHO/FIP Training Workshop
Hyatt Regency Hotel
Sahar Airport Road
Andheri East, Mumbai, India
28 April 2008 – 2 May 2008
2. Simon Mills | April 20082 |
Pharmaceutical Development with Focus
on Paediatric formulations
Pharmaceutical packaging – an overview
including some considerations for paediatrics
Presented by:
Name: Simon Mills
Contact details:
Simon.n.mills@gsk.com
3. Simon Mills | April 20083 |
• Choosing the most Appropriate Primary Pack
• Blister Packs
• Containers & Closures
• General Overview
• Bottles
• Blister Packs
• Inhalation / IntraNasal products
• Regulatory
• US, EU, Pharmacopoeial
• Extractable & Leachables
• Packaging Development considerations through to Launch
Introduction
4. Simon Mills | April 20084 |
• As far as CMC considerations are concerned, paediatric and adult
dosage forms can be treated in much the same way. There will be
particular areas to focus attention on for paediatric products:
• There may be lower limits of acceptable levels of impurities, extractables and
leachables resulting from product/pack interaction.
• Extra or novel devices to facilitate dosing or compliance can be associated with
paediatric products, e.g. spacers with MDIs, syringes for oral dosing, nebulisers.
It will be important to ensure that all contact materials are suitable and well
controlled. For new materials/devices, this will necessitate extensive evaluation.
• Children must be protected from the risk of unsupervised access to medicines –
this applies equally to paediatric and adult drug products. The need for child-
resistant (CR) packaging will need to be assessed, balanced against the
adjudged risk in accidental ingestion of the drug product itself; (some territories
insist on CR packs; US requirements detailed in 16 CFR §1700).
Specific paediatric considerations
5. Simon Mills | April 20085 |
Protection
– stability test conditions
Commercial
– image
– market requirements/trends
– dosing/patient compliance
– security/tamper evidence
– manufacturing
– economics - COG
BASIC REQUIREMENTS
Legislation
– e.g. EC Packaging and
Packaging Waste Directive
Compatibility
PACKAGING: Choosing the most appropriate pack
Regulatory
Corporate
– Global Quality Policies
6. Simon Mills | April 20086 |
ADDITIONAL DRIVERS & FUTURE CHALLENGES:
Moisture sensitive drugs increasing barrier requirements
Novel delivery systems
Emphasis on speed to market
Control of R&D Expenditure/resource - number of stability
studies required
Global - Regional - Local packs
Anti-counterfeiting, illegal cross-border trading
Pharmacogenomics - Personalised medicines
Demographic change - Ageing population
PACKAGING: Choosing the most appropriate pack
7. Simon Mills | April 20087 |
Some factors are territory-specific, e.g.
• Environment
– EU Packaging and
Packaging Waste Directive
– US - no direct equivalent
Presentation
– e.g. for solid dose
• US prefers bottles
• EU/RoW prefer blister
packs
Child resistance requirements
– US
• Legal requirement with few
exceptions
– EU/RoW
• Legal requirement in only 4 EU
member states & for very limited
list of products
PACKAGING: Choosing the most appropriate pack
8. Simon Mills | April 20088 |
Packaging: WVTR
The water vapour transmission rate (WVTR) through the container is
determined by:
– Container wall thickness
– Permeability of the packaging material
– Difference between the external and internal relative humidity environments
• Driving force for the water flux through the container
The theoretical rate of water permeation through a standard 60-cc
HDPE bottle when stored at 40°C/75%RH has been determined:
– This equated to an uptake of 1mg of water per day.
– So, even if a product is packed under low water vapour conditions the relative
humidity conditions within the container will re-equilibrate to 50% within 1 day.
9. Simon Mills | April 20089 |
Packaging: Desiccants
Desiccants have been utilised to control the exposure of products to the
ingress of moisture.
Desiccants vary in their capacity and the rate that they adsorb/absorb
ingressed moisture.
– Silica gel is very efficient at absorbing moisture at high relative humidities, but
comparatively poor at lower relative humidities.
– Molecular sieve desiccants - the opposite scenario prevails.
– As a consequence, more molecular sieve is required at higher relative humidities, and
the greater the handling precautions that are required during packaging operations.
– Molecular sieve approved in EU for pharmaceuticals, not by FDA in US.
– Based on the calculated WVTR of known container components and the rate of moisture
adsorbed by desiccants, the amount of desiccant that would be required to maintain a
specified relative humidity over the product’s shelf-life can be determined.
10. Simon Mills | April 200810 |
Barrier Properties (typical MVTR g/m2/day 38°C/90%RH)
Cold Form Aluminium 0.00
Aclar ®
33C 0.08
Aclar ®
UltRx2000 0.11 - 0.12
Aclar ®
22C 0.22
Aclar ®
SupRx 900 0.23 - 0.26
Aclar ®
22A 0.31 - 0.34
PVC/80g PVDC 0.31
Aclar ®
Rx160 0.39 - 0.42
Aclar ®
33C 0.42
PVC/60g PVDC 0.47 - 0.6
PVC/40g PVDC 0.7 - 0.75
PP 0.7 - 1.47
PVC 2.4 – 4
Aclar ® is a registered trade mark of Allied Signal
PACKAGING: Choosing the most appropriate pack
11. Simon Mills | April 200811 |
Packaging: OVTR
Similar considerations are
relevant to protection of
products that are labile to
oxidative degradation. The
permeability of plastic
containers to oxygen
ingress has also been
evaluated (OVTR), and is
summarised here.
Pack OVTR
(g. mm/(m2
. day))
LDPE 241
HDPE 102
Polystyrene 127
Polycarbonate 114
Polypropylene 89
PVC 4
PET 2
12. Simon Mills | April 200812 |
Packaging Development
The theoretical rate of oxygen permeation through a standard 30-cc HDPE
bottle when stored in a well sealed container has been determined:
– This equated to an uptake of 0.2 mMol of oxygen per year
In addition to permeation through the container walls, the key
vulnerability in any container-closure system is the closure.
With screw-topped closures, leakage can be significant.
Hence for oxidatively labile dosage forms an oxygen-impermeable seal is
required and induction heat-sealed containers are particularly useful.
Levels of oxygen in the headspace of the container-closure can be significant,
and packaging under an inert atmosphere, although doable, is problematical.
13. Simon Mills | April 200813 |
What is First Intent?
– Preferred range of pack/material options to be used for
new products
– Agreed between R&D and factory
– Identical global materials
– Fully aligned with Procurement sourcing strategies
– Secure/robust sourcing
– Minimised R&D resource
– Supports supply site transfers (like for like; identical)
PACKAGING: First Intent
14. Simon Mills | April 200814 |
MATERIALS (hierarchy of choice based on product stability)
– Material should preferably be opaque white unless clear is a specific market requirement (e.g. US, Japan)
– Aclar® should be restricted to applications where cold form is not technically or commercially acceptable due to
product or pack size, ie larger products (further guidance to be defined)
1. PVC 250µm
2. PVC/PVDC 250µm/60gsm
4. PVC/Aclar® UltRx 2000
3. Cold Form 25 OPA/45 Al/ 60 PVC
Aclar® is registered trademark of Honeywell Inc
PACKAGING: First Intent – Blister base
15. Simon Mills | April 200815 |
• Reduction of complexity
• Standardisation and rationalisation
of components
• Reduced number of change-overs at
factory sites
• Reduction in resource demand
• R&D, Pack Dev, Procurement, Sites
use ‘off the shelf’ solution for
majority of products.
• Flexibility across factory sites
without increased Regulatory
activity.
• Risk Mitigation
• Commercial Leverage
Reduced Complexity
Maintaining Flexibility
Reduced Complexity
Maintaining Flexibility
CurrentCurrent
FutureFuture
First Intent: Bottles and Closures - Benefits
16. Simon Mills | April 200816 |
BOTTLE
Glass
– type III (solids)
– type I (for inhaled solutions)
Plastic
– low density polyethylene LDPE
– high density polyethylene HDPE
– polypropylene PP
– polyester PET, PETG
– Cyclo-olefin copolymer (COC)
PACKAGING: Bottles
17. Simon Mills | April 200817 |
Plastic - wadless or lined, CR (child resistant), CT (continuous
thread), snap fit
Metal - screw, ROPP
Liner – cork, pulpboard, EPE; flowed in gasket
– product contact materials/facings : PVDC, Saran, Saranex,
Melinex, EPE, Vinyl, Foamed PVC
Induction heat seals
PACKAGING: Closures
18. Simon Mills | April 200818 |
THERMOFORM BLISTERS
– plastic base web
– blister formed with aid
of heating
– low to high barrier
PACKAGING: Solid Dose – Blister Packs
- PVC
- PVDC or Aclar®
Lidding Foil – typically 20 micron Al
Film - eg PVC, PVC/PVDC, PVC/PE/PVDC, PVC/Aclar®
- Overlacquer
- Heat seal lacquer
- Print
- Aluminium
- Primer
Product contact layers: For PVC or PVC/Aclar® = PVC
For PVC/PVDC = PVDC
For Lid foil = heat seal lacquer
19. Simon Mills | April 200819 |
Foil Laminate – e.g. OPA/foil/PVC, or
OPA/foil/PP
Lidding FoilCOLD FORM BLISTER
– blister formed mechanically (no heat)
– high barrier
PACKAGING: Solid Dose – Blister Packs
- PVC (may be PP)
- OPA Film
- Aluminium foil
- Primer/Adhesive
- Primer/Adhesive
Product contact layers:
For base = PVC (or PP)
For lid foil = heat seal lacquer
20. Simon Mills | April 200820 |
Lidding Foil
Foil Laminate – e.g. OPA/foil/PVC
TROPICALISED BLISTER
– thermoform blister plus cold form tray
– once tray opened, in use life determined by
primary thermoform blister
– high barrier before use
PACKAGING: Solid Dose – Blister Packs
Film – e.g. PVC, PVC/PVDC
Product contact layers:
For PVC = PVC
For PVC/PVDC = PVDC
For Lid foil = heat seal lacquer
21. Simon Mills | April 200821 |
Packaging challenges (4FDC)
A 4-API combination anti-TB tablet:
Rifampicin 150 mg
Isoniazid 75mg
Pyrazinamide 400mg
Ethambutol 275mg
TOTAL API weight: 900mg
Tablet weight: 1.3g
The technical challenges:
Big tablet
Problem APIs !!
Rifampicin is vulnerable to oxidative degradation and hydrolysis, it is light sensitive
and it reacts with isoniazid. It also exhibits solid-state polymorphism.
Isoniazid reacts with aldehydes/reducing sugars….& rifampicin → major degradant
Ethambutol (2HCl) is hygroscopic, attracting moisture into the tablet to form a slightly
acidic solution that encourages the rifampicin/isoniazid interaction!
Pyrazinamide…..seems to be OK !
22. Simon Mills | April 200822 |
Packaging challenges (4FDC)
The solution:
Packaging:
– Non-permeable (moisture and oxygen) material
– Do not remove from primary packaging until use
– Avoid repackaging
– Protect from light
Also:
Excipients: no sugar/lactose (isoniazid)
Rifampicin used as “as is” powder (no granulation)
Maintain low water content of tablets (USP ≤ 3.0%)
23. Simon Mills | April 200823 |
Metered dose inhaler
Nebules
PACKAGING: IH and IN Products
Dry Powder Inhalers
Intranasal
24. Simon Mills | April 200824 |
PACKAGING: Key Regulatory Guidance - US
Guidance for Industry, Container
Closure Systems for Packaging of
Human Drugs and Biologics
Guidance for Industry, Changes to an
Approved NDA or ANDA
25. Simon Mills | April 200825 |
PACKAGING: Key Regulatory Guidance - EU
CPMP/QWP/4359/03 – Guideline on Plastic
Immediate Packaging Materials - specific to
plastics only
Guideline on Dossier Requirements for Type
1A and Type 1B Notifications
KEY POINT TO NOTE
EU does NOT have a consolidated
container/closure guideline (cf FDA)
26. Simon Mills | April 200826 |
FDA & CPMP (CHMP) Regulated
Baseline Statement of Safety
– Defines
• acceptable starting materials
• acceptable additives and processing aids
• limits on residues
• limits on leachables (e.g. specific migration limits)
– Based upon
• Acceptable or Tolerable Daily Intake in FOOD
NOTE: US and EU do not use same calculations
PACKAGING: Food Contact Approval - Relevance
27. Simon Mills | April 200827 |
EXTRACTABLES and LEACHABLES: Definitions
Extractable
– Compounds that can be extracted from
elastomeric, plastic components or coating
of the container and closure system when in
the presence of an appropriate solvent(s)
Leachable
– Compounds that leach from the elastomeric,
plastic components or coatings of the
container and closure system as a result of
direct contact with the formulation of the
drug product. Can get interaction with a
product component to produce an impurity
that requires stability monitoring.
28. Simon Mills | April 200828 |
EXTRACTABLES and LEACHING:
Practical examples of Issues
•Polyaromatic hydrocarbons (PAH) detected in CFC-filled
MDIs (c.1990)
– Prompted the first concerted efforts to look for leachables in MDIs
• Vanillin detected in solutions for inhalation packed in LDPE
containers
– Source: migration through LDPE container wall from cardboard outer
packaging. Protective Al foil laminate overwrap introduced.
Di-ethylhexyl phthalate (DEHP)
– Plasticizer in PVC; detected, for example, in TPN fat emulsions probably
via infusion tubing set
– Neonates have particular sensitivity to DEHP
29. Simon Mills | April 200829 |
EXTRACTABLES and LEACHING: Considerations
Clinical concerns:
– A potentially sensitive, compromised (especially paediatric) patient population
– Safety for both acute and chronic administration
Regulatory requirements:
– FDA requirements
– Included in CPMP guideline 3AQ10a and CPMP/QWP/4359
Extractables: control of quality of packaging materials and robust
relationship with suppliers, e.g. change control.
Leachables: comprehensive stability package – long-term storage condition and
accelerated stability assessment for drug product in pack to cover shelf-life of
the product
• Consistency in materials/components (Specifications, DMFs)
• Control of packing material and product manufacture
• Control for unintended contaminants
30. Simon Mills | April 200830 |
Packaging Development
Objective
– To ensure timely and robust selection of the primary pack for
clinical trial and commercial supply.
Recommended approach:
– To use, where possible, a limited range of standard,
well-characterised pack materials and packs.
– To ensure thorough testing, characterisation and understanding
of these selected pack materials and packs.
31. Simon Mills | April 200831 |
Phase I – FTIH & Phase II Clinical Supply
Objective:
– Selection of packs for clinical supply
Strategy:
– Aim to use
• Limited range of standard, characterised packs, e.g. HDPE bottles for
solid dose forms
• Inert packs, e.g. fluororesin laminated injection stoppers
– Packs and materials chosen to ensure pharmacopoeial and
regulatory compliance is well understood
– Material performance is well characterised or known
– Pack selection is supported by stability testing for each product
32. Simon Mills | April 200832 |
Phase II – III, Commercial Pack Development
Objective:
– Identification, development and testing of commercial pack options
Approach:
3. Development Stability Testing
2. Material Selection & Testing
1. Identify Pack Options
6. Pivotal Stability Testing
5. Pack Selection
4. Controls Defined
33. Simon Mills | April 200833 |
Pack options are identified to meet:
– Product attributes, e.g. dosage form, physical and chemical robustness
– Product protection needs, e.g. moisture & gas sensitivity, thermal stability, photostability,
chemical compatibility, etc
– Clinical requirements, e.g. dosing regimen, titration dosing, route of administration, need
for dosing device
– Patient requirements, e.g. specific handling requirements, patient handling studies
– Commercial requirements, e.g. market presentation, pack sizes, market specific needs,
patient handling needs
– Manufacturing requirements, e.g. equipment capability, critical process parameters
– Regulatory requirements, e.g. material compliance, pharmacopeial monographs
1. Identify Pack Options
34. Simon Mills | April 200834 |
• Product contact materials chosen to meet global and local regulations.
• Product contact materials, particularly, plastics confirmed as compliant with
relevant food contact regulations, e.g. US, EU etc
• Pharmacopoeial compliance established, e.g. USP, Ph Eur, JP
• Performance testing conducted, e.g., moisture permeation, light
transmission
• Chemical characterisation, e.g. extractables and leachables studies,
especially for parenteral, ophthalmic and inhalation products
• Toxicological assessment of extractables and leachables conducted
• Maximise pack and product knowledge and understanding and achieve
commercial efficiency by using a limited range of First Intent, preferred pack
materials, wherever possible.
2. Material Selection & Testing
35. Simon Mills | April 200835 |
• Development stability testing used to
• Understand and explore stability in selected pack option
• Predict long term stability
• Confirm product protection or need for more protective packs, e.g. need for
• Inclusion of desiccants for moisture protection
• Higher barrier blister films or need for foil/foil blisters
• protective overwrap
• Confirm compatibility
• Identify and explore pack/product interaction
• These are key data used to make a final pack selection.
3. Development Stability Testing
36. Simon Mills | April 200836 |
• Data from material and product testing used to
identify critical quality and process attributes for
pack and packaging process, e.g.
• Need for RH controls during packing
• Need for inert gassing of pack headspace
• Seal integrity testing
• Need for extractables testing as a routine control
• Manufacturing controls/specifications for the pack
components and suppliers, e.g. dimensional and
performance specifications, need for clean room
manufacture, etc.
• Manufacturing controls for the packaging process
4. Controls Defined
37. Simon Mills | April 200837 |
• Data from the previous steps, together with the
clinical, patient, commercial and manufacturing
requirements, are used to identify and agree the
intended market packs.
• Pivotal stability testing conducted in the
selected markets packs, to
• Confirm compatibility and product stability
• Support product registration submission
5. Pack Selection
6. Pivotal Stability Testing
38. Simon Mills | April 200838 |
Phase 3 - Launch
Between Phase 3 and Launch
– Secondary packaging is defined
• note, if needed for product protection, this will be defined with
the primary pack and included in pivotal stability
– Define market presentations, graphics, patient information leaflets
– Conduct line, engineering and technical trials on pack components and
equipment
– Conduct any necessary validation of packaging processes
39. Simon Mills | April 200839 |
Pack Changes?
Recommended aim:
– to avoid pack changes between pivotal stability and launch by ensuring a Quality-
by-Design approach to pack selection and understanding of product stability and
packaging.
However, changes can occur at late stage due to, for example…
– Unpredictable outcome in pivotal stability assessment
• Newly identified impurities
• Requirement for tighter specification limits
These tend to drive need for more protective packs, e.g.
– Inclusion of desiccant in bottle packs
– Need for higher barrier (e.g. foil/foil) blister packs
By use of First Intent pack materials and packs, we aim to have a
thorough understanding of our materials to minimise impact of change
and have readily available, well characterised pack options.
40. Simon Mills | April 200840 |
Summary
• Choosing the most Appropriate Primary Pack
• Blister Packs
• Containers & Closures
• General Overview
• Bottles
• Blister Packs
• Inhalation/IntraNasal products
• Regulatory
• US, EU, Pharmacopoeial
• Extractable/Leachables
• Packaging Development considerations through to Launch
ANY QUESTIONS PLEASE?
Editor's Notes
At the opposite extreme - For Perfumes then development of the pack is as important as development of the product.
The same is true for pharmaceuticals, and we need to be nearer this end of the spectrum and not the end game.
Pack should be developed and tested alongside the product
Treat no different to product. As we will see in a minute in numerous cases the same guidelines, eg, ICH Q6A, CPMP DPS and Stability guidelines, are equally applicable to packaging.
Perhaps a useful an would be excipient compatibility and to GMP.
Just as GMP is not something you can add at the end of a process, if looking for effective ST’s, then same is true for is packaging.
Let’s start with Packaging is not an end game activity.
What do I mean by this?
I have worked in this industry for 30 years, most of my career having been spent in packaging. Whilst I have seen many changes in that time, one thing which has tended to remain constant is that for many people in the industry packaging is something that is bolted on at the end, or something which somebody else sorts out for you.
At the opposite extreme - For Perfumes then development of the pack is as important as development of the product.
The same is true for pharmaceuticals, and we need to be nearer this end of the spectrum and not the end game.
Pack should be developed and tested alongside the product
Treat no different to product. As we will see in a minute in numerous cases the same guidelines, eg, ICH Q6A, CPMP DPS and Stability guidelines, are equally applicable to packaging.
Perhaps a useful an would be excipient compatibility and to GMP.
Just as GMP is not something you can add at the end of a process, if looking for effective ST’s, then same is true for is packaging.
At the opposite extreme - For Perfumes then development of the pack is as important as development of the product.
The same is true for pharmaceuticals, and we need to be nearer this end of the spectrum and not the end game.
Pack should be developed and tested alongside the product
Treat no different to product. As we will see in a minute in numerous cases the same guidelines, eg, ICH Q6A, CPMP DPS and Stability guidelines, are equally applicable to packaging.
Perhaps a useful an would be excipient compatibility and to GMP.
Just as GMP is not something you can add at the end of a process, if looking for effective ST’s, then same is true for is packaging.
At the opposite extreme - For Perfumes then development of the pack is as important as development of the product.
The same is true for pharmaceuticals, and we need to be nearer this end of the spectrum and not the end game.
Pack should be developed and tested alongside the product
Treat no different to product. As we will see in a minute in numerous cases the same guidelines, eg, ICH Q6A, CPMP DPS and Stability guidelines, are equally applicable to packaging.
Perhaps a useful an would be excipient compatibility and to GMP.
Just as GMP is not something you can add at the end of a process, if looking for effective ST’s, then same is true for is packaging.